Understanding Nonadherence and Discontinuation in Mental Health Treatment
If you or a loved one has been prescribed psychiatric medication, you may have experienced doubt at some point:
“Do I really need this?”
“What if this changes who I am?”
“I feel better — can I stop now?”
“The side effects aren’t worth it.”
Medication hesitation, partial adherence, and discontinuation are widespread in psychiatric care. In fact, only about half of individuals with chronic mental health conditions maintain adequate treatment adherence over time.
As a Psychiatric Mental Health Nurse Practitioner providing outpatient psychiatric care in Delaware, I routinely discuss these concerns with adolescents and adults. These conversations are not signs of failure. They are an expected and essential part of treatment.
Understanding the relationship between patients and medication is often more critical than the prescription itself.
Medication Hesitation Is Not Irrational
Psychopharmacology is powerful. It can reduce suicidality, stabilize mood, decrease psychosis, and restore functioning. But medications also carry:
- Side effects
- Social stigma
- Cultural beliefs about mental illness
- Fear of dependency
- Past negative treatment experiences
The American Society of Clinical Psychopharmacology (ASCP) emphasizes that deprescribing discussions must account for patient beliefs, expectations, cultural values, prior experiences, and the psychological meaning of medication use.
For some individuals, medication represents stability.
For others, it symbolizes illness, loss of autonomy, or fear of long-term dependence.
Both reactions are human.
How Common Is Nonadherence?
Nonadherence occurs across all psychiatric diagnoses:
In chronic mental health conditions, adherence rates are often around 50%.
For antidepressants, up to 25% of patients discontinue within the first month, and as many as 68% stop within three months.
In bipolar disorder, nonadherence rates may approach 40% or higher.
Importantly, adherence is not all-or-nothing. It exists along a spectrum:
- Delayed initiation
- Intermittent dosing
- Dose reduction without discussion
- Early discontinuation
- Complete cessation
Understanding why someone stops is more clinically meaningful than labeling them “noncompliant.”
Why Do Patients Stop Psychiatric Medication?
Research consistently identifies several recurring themes.
Side Effects
Adverse effects are among the most common reasons for discontinuation across diagnoses.
These may include:
- Sexual dysfunction
- Weight gain
- Sedation
- Emotional blunting
- Cognitive dulling
Patients often tolerate more distress from side effects than clinicians realize.
Feeling Better
A common and paradoxical reason for stopping medication is improvement.
When symptoms decrease, patients may conclude:
“Maybe I never needed it.”
However, evidence shows that relapse risk increases after premature discontinuation across multiple psychotropic classes.
Maintenance treatment duration should be individualized and discussed collaboratively.
Perceived Lack of Effectiveness
Before assuming a medication “failed,” the ASCP consensus strongly recommends verifying adherence and the adequacy of the trial.
Sometimes what appears to be medication resistance is actually:
- Inconsistent dosing
- Early discontinuation
- Missed refills
- Incorrect expectations about the onset
This is why structured follow-up and measurement-based care are critical.
Psychological Meaning of Medication
The ASCP notes that conscious and unconscious beliefs about medication influence patient reactions to discontinuation discussions.
Some patients fear:
- Losing a “safety net.”
- Relapse
- Being judged as weak for needing medication
Others fear:
- Being controlled
- Long-term dependency
- Identity change
These beliefs deserve exploration—not dismissal.
Risks of Abrupt Discontinuation
Stopping psychiatric medication suddenly can lead to:
- Symptom relapse
- Withdrawal or discontinuation syndromes
- Loss of treatment responsiveness in some cases
A 2025 systematic review found that non-response occurred in 4–57% of individuals who stopped and restarted previously effective antidepressants.
Across medication classes, discontinuation requires structured planning and monitoring to reduce relapse and destabilization risk.
Abrupt cessation is rarely advisable.
What Evidence-Based Deprescribing Looks Like
Deprescribing is not abandonment of care. It is a structured clinical process.
The ASCP outlines key principles:
- Reassess medication utility periodically
- Conduct a formal risk-benefit analysis
- Ensure sustained remission before tapering
- Make one medication change at a time
- Increase follow-up frequency during taper
- Use shared decision-making
Deprescribing should never occur without assessing adherence and ensuring an adequate therapeutic trial.
The goal is thoughtful modification—not reflexive continuation or impulsive discontinuation.
The Therapeutic Alliance Matters Most
Research across psychiatric disorders consistently highlights that adherence improves when:
- Patients feel heard
- Side effects are proactively addressed
- Treatment goals are collaborative
- Cultural beliefs are respected
- Monitoring is structured and consistent
The APA emphasizes that treatment decisions should be individualized and made collaboratively with patients and families whenever possible.
Medication works best when the relationship works.
How I Approach Medication Hesitation in Practice
In outpatient psychiatric care in Delaware, discussions about medication hesitancy typically include:
- Exploring past medication experiences
- Clarifying fears about dependence or identity change
- Reviewing realistic expectations for onset and benefit
- Proactively addressing side effects
- Discussing the duration of treatment transparently
- Planning taper strategies before medication is started
Patients are more comfortable beginning treatment when they understand:
- Why is the medication recommended
- What improvements to expect
- What side effects to watch for
- That stopping can be discussed safely
Medication should feel collaborative—not imposed.
When to Reevaluate Medication
A structured review is appropriate when:
- Side effects outweigh benefits
- Treatment goals have been achieved
- There is no partial therapeutic response after an adequate trial
- The diagnosis has changed
- Polypharmacy becomes unnecessarily complex
The ASCP consensus emphasizes that medication regimens should be systematically reassessed at least annually.
Stability does not eliminate the need for evaluation.
The Bottom Line
Medication hesitation, partial adherence, and discontinuation are common and understandable.
They are not signs of weakness or failure. They are signals that a deeper discussion is needed.
Psychiatric medication management is not just about prescribing. It is about:
- Understanding the patient’s relationship to medication
- Monitoring response and tolerability
- Adjusting thoughtfully
- Engaging in shared decision-making
- Preventing relapse while respecting autonomy
If you are in Delaware and struggling with uncertainty about psychiatric medication — whether starting, continuing, or tapering — a structured outpatient psychiatric evaluation can help clarify:
- Whether the medication remains necessary
- Whether adjustments are appropriate
- How to taper safely if indicated
- How to balance long-term stability with quality of life
In mental health care, the goal is not to be blind to adherence.
It is an informed, collaborative, and sustainable treatment.
